Evaluation of the clinical efficacy of Apremilast tablets in the treatment of psoriasis

Apremilast As aPDE4 inhibitor, it has been recognized by multiple international guidelines in the treatment of plaque psoriasis. It is easy to take orally, does not require injections, and does not require monitoring, making it an important treatment option for patients with mild to moderate psoriasis. The evaluation of clinical effects is mainly carried out from three aspects: improvement of skin symptoms, relief of joint symptoms and improvement of quality of life.

Judging from clinical experience, apremilast can significantly improve skin plaque psoriasis, especially in mild to moderate patients. After several weeks of continuous treatment, most patients will see a reduction in the scope of the rash, a reduction in scales, and a reduction in itching. Although apremilast has a slightly slower onset of action than some potent biologics, it provides mild and long-lasting effects, making it suitable for patients requiring long-term management. For patients with psoriatic arthritis, apremilast also shows a certain ability to improve joint symptoms, reducing joint stiffness and pain, thereby improving range of motion.

In long-term follow-up, patients' quality of life is often an important indicator for efficacy evaluation. Studies have shown that patients treated with apremilast experience positive improvements in daily life and mental state, with some even reporting a return to social functioning and emotional self-confidence. This shows that Apremilast not only brings relief to skin symptoms, but also has value in the overall health experience.

It is worth mentioning that apremilast is not a panacea, and its efficacy varies among different individuals. Some patients' skin improves faster, while some people take longer to see significant changes. When doctors evaluate the efficacy, they usually combine the psoriasis severity score (such asPASI) and the patient's self-perception to comprehensively judge whether to continue maintenance treatment.

Reference materials:https://go.drugbank.com/drugs/DB05676